261 related articles for article (PubMed ID: 36316100)
1. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.
Caso V; de Groot JR; Sanmartin Fernandez M; Segura T; Blomström-Lundqvist C; Hargroves D; Antoniou S; Williams H; Worsley A; Harris J; Caleyachetty A; Vardar B; Field P; Ruff CT
Heart; 2023 Jan; 109(3):178-185. PubMed ID: 36316100
[TBL] [Abstract][Full Text] [Related]
2. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
[TBL] [Abstract][Full Text] [Related]
3. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.
Joosten LPT; van Maanen R; van den Dries CJ; Rutten FH; Hoes AW; Granger CB; Hemels MEW; Geersing GJ; van Doorn S
Open Heart; 2023 May; 10(1):. PubMed ID: 37169490
[TBL] [Abstract][Full Text] [Related]
5. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
7. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
9. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
10. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies.
Sang C; Chen J; Sun J; Lai Y; Liu X; Zhu W
Eur J Clin Invest; 2022 Oct; 52(10):e13819. PubMed ID: 35643840
[TBL] [Abstract][Full Text] [Related]
11. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
[TBL] [Abstract][Full Text] [Related]
12. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies.
Guo Z; Ding X; Ye Z; Chen W; Chen Y
Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988
[TBL] [Abstract][Full Text] [Related]
14. Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.
Delesie M; Ballet A; Hillegeer C; Desteghe L; Dendale P; Heidbuchel H
Clin Drug Investig; 2022 Sep; 42(9):775-786. PubMed ID: 35986867
[TBL] [Abstract][Full Text] [Related]
15. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
[TBL] [Abstract][Full Text] [Related]
16. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
17. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
18. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
19. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
20. Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry.
Tütüncü S; Olma M; Kunze C; Dietzel J; Schurig J; Fiessler C; Malsch C; Haas TE; Dimitrijeski B; Doehner W; Hagemann G; Hamilton F; Honermann M; Jungehulsing GJ; Kauert A; Koennecke HC; Mackert BM; Nabavi D; Nolte CH; Reis JM; Schmehl I; Sparenberg P; Stingele R; Völzke E; Waldschmidt C; Zeise-Wehry D; Heuschmann PU; Endress M; Haeusler KG
J Neurol; 2022 Jan; 269(1):470-480. PubMed ID: 34718884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
